Skip to page content

Prescription Drug Benefits

Commentary

Why States' 'Netflix Model' Prescription Drug Arrangements Are No Silver Bullet

Despite the buzz and catchy notion that subscription models are “Netflix for drugs,” it's hard to come up with a theoretical case that supports subscription models over traditional price negotiation between payers and manufacturers over a per-dose or per-unit price.

Jul 1, 2020
Journal Article

Journal Article

How Increasing Medical Access to Opioids Contributes to the Opioid Epidemic: Evidence from Medicare Part D

The national growth in opioid supply explains 75% of the national rise in opioid treatment admissions and the diversion component is a critical driver of the opioid epidemic.

Jun 26, 2020
Report

Report

Subscription Models for Prescription Drugs: The Motivation, Potential, and Limitations of a New Payment Model

The authors argue that, conceptually, the main advantage of subscription models over traditional prescription drug payment arrangements is that they could reduce some sources of uncertainty in spending for payers and in revenue for manufacturers.

May 21, 2020
Journal Article

Journal Article

Association of Medicare Part D Benzodiazepine Coverage Expansion With Changes in Fall-Related Injuries and Overdoses Among Medicare Advantage Beneficiaries

This study found an increase in the rate of overdose after Medicare Part D coverage began to include benzodiazepines among adults aged 65 to 69 years and 80 years or older and an increase in the rate of fall-related injury in adults 80 years or older.

May 5, 2020
Report

Report

RAND Medicare Advantage (MA) and Part D Contract Star Ratings Technical Expert Panel November 7th, 2019 Meeting

On November 7, 2019, the RAND Corporation convened a Technical Expert Panel (TEP) web meeting to gather input on analyses that could be conducted to further enhance the Medicare Advantage (MA) and Part D Contract Star Ratings program.

Feb 7, 2020
Commentary

The Promise and Peril of Offshoring Prescription Drug Pricing

Most Americans, including Congress and the president, agree that prescription drug prices are too high. Policy proposals from both major parties could promise some relief. Several of them look to drug prices in other countries to help set prices in the United States.

Sep 16, 2019
Report

Report

RAND Medicare Advantage (MA) and Part D Contract Star Ratings Technical Expert Panel April 30, 2019 Meeting

On April 30, 2019, the RAND Corporation convened a Technical Expert Panel (TEP) web meeting to gather input on analyses that could be conducted to further enhance the Medicare Advantage (MA) and Part D Contract Star Ratings program.

Sep 6, 2019
Report

RAND Medicare Advantage (MA) and Part D Contract Star Ratings Technical Expert Panel October 30th 2018 Meeting

On October 30, 2018, the RAND Corporation convened a Technical Expert Panel (TEP) web meeting to gather input on analyses that could be conducted to further enhance the Medicare Advantage (MA) and Part D Contract Star Ratings program.

Jan 18, 2019
Multimedia

Albert P. Williams Lecture on Health Policy: What's the Fair Price of a Drug?

In this Events @ RAND podcast, Ezekiel J. Emanuel delivers the 2018 Albert P. Williams Lecture on Health Policy. Emanuel explains why drug prices are so high and proposes a policy solution.

Oct 17, 2018
Report

Report

RAND Medicare Advantage (MA) and Part D Contract Star Ratings Technical Expert Panel May 31st 2018 Meeting

On May 31, 2018, the RAND Corporation convened a Technical Expert Panel (TEP) to gather input on analyses that could be conducted to further enhance the Medicare Advantage (MA) and Part D Contract Star Ratings program.

Aug 23, 2018
Journal Article

Journal Article

Impact of Issuing Longer- Versus Shorter- Duration Prescriptions: A Systematic Review

UK recommendations to provide shorter prescriptions are not substantiated by the current evidence base.

Mar 14, 2018
Report

Report

Modeling the Economic Impact of a California Workers' Compensation Formulary

This report estimates the potential impacts of a California Workers' Compensation formulary in terms of changes in prescription drug use and spending and discusses the potential broader impacts of these changes on the California economy.

Jul 17, 2017
Journal Article

Journal Article

Impact of Prescription Drug Monitoring Programs (PDMPs) on Opioid Utilization Among Medicare Beneficiaries in 10 U.S. States

Implementation of a prescription drug monitoring program in 10 states was associated with a reduction in overall volume of opioid drugs prescribed.

Jun 14, 2017
Commentary

Effects of Removing Maternity Care and Mental Health Treatment from Coverage Requirements

The American Health Care Act passed by the U.S. House of Representatives to repeal and replace the Affordable Care Act allows states to waive benefits that the ACA deemed “essential.” Dropping maternity care coverage, for example, would reduce premiums by 5 percent but increase out-of-pocket spending for new mothers.

May 18, 2017
Journal Article

Journal Article

Lessons Learned from an Integrated MTM Program

A community health center in western Massachusetts offers a model of integrated care, in which pharmacists play key roles in decision making and charting.

May 11, 2017
Commentary

Easing the Pain When Critical Medications Are No Longer Covered

Allowing insurance companies to limit the drugs they cover is necessary to give them leverage that can result in lower medication costs for all patients. Still, there are ways to make the process more transparent and manageable.

Oct 28, 2016
Report

Implementing a Drug Formulary for California's Workers' Compensation Program

This report supports the California Division of Workers' Compensation's efforts to establish a drug formulary by comparing existing workers' compensation formularies and analyzing options for designing and implementing the formulary.

Aug 25, 2016
Journal Article

Prescription Drug Use Rises, Out-of-Pocket Spending Drops Among Those Newly Insured Under the ACA

A study of nearly 7 million prescription drug users' experiences provides strong evidence that the Affordable Care Act has increased treatment rates while reducing out-of-pocket spending, particularly for those with certain chronic health conditions.

Aug 19, 2016
News Release

News Release

Prescription Drug Use Rises, Out-of-Pocket Spending Drops Among Individuals Newly Insured Under Affordable Care Act

A study of nearly 7 million prescription drug users' experiences provides strong evidence that the Affordable Care Act has increased treatment rates while reducing out-of-pocket spending, particularly for those with certain chronic health conditions.

Aug 17, 2016
Journal Article

Journal Article

Adverse Selection in Retiree Prescription Drug Plans

Claims data from a large U.S. employer that introduced changes in its medical and drug coverage offerings in 2002 for non-Medicare eligible retirees.

Jun 27, 2016

1
2
3
4
5
Next

Research conducted by

RAND Health Care